Trials / Completed
CompletedNCT01122875
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MFGR1877S | Intravenous repeating dose |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2010-05-13
- Last updated
- 2016-11-02
Locations
12 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01122875. Inclusion in this directory is not an endorsement.